A Phase I Pharmacokinetic and Randomized Phase II Trial of Neoadjuvant Treatment With Anastrozole Plus AZDO530 in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer

The purpose of this study is to test the tolerability and efficacy or AZD0530 when used together with Anastrozole in patients with ER+ and/or PR+ postmenopausal breast cancer. AZD0530 (also known as saracatinib), is an investigational drug which acts in a different way than Anastrozole or related drugs do. It blocks the action of an enzyme called SRC (pronounced ?sark?). By doing this, AZD0530 also blocks some of the signals which are needed for the tumor to grow, spread, or become resistant to standard treatments such as Anastrozole. In this research study, AZD0530 is used before the time of primary surgery to remove the tumor. It is intended to improve and to aid the effectiveness of the standard hormonal therapy (Anastrozole) and surgery. The term ?neoadjuvant? is commonly used to refer to treatment before the primary treatment of surgery.

Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.

Investigator(s):

Intervention(s):

  • drug : Placebo
  • drug : ADZ0530
  • drug : Anastrozole
  • genetic : Tumor Tissue Collection for Genetic and Molecular Studies
  • procedure : Core Biopsy
  • procedure : Definitive Surgery
  • procedure : Pharmacokinetic studies

Phase: Phase 1/Phase 2

Eligibility

Ages Eligible For Study:

18 Years - N/A

External Links

Explore related trials

Contact information

Primary Contact:

Annabel Castaneda 650-498-7977

Stanford University School of Medicine 300 Pasteur Drive Stanford, CA 94305

Stanford Medicine Resources:

Footer Links: